Contact Us
Drug Search Results
More Filters [+]

Daclizumab

Alternative Names: daclizumab, zenapax, biib-019, biib019, biib 019, zinbryta
Latest Update: 2024-03-07
Latest Update Note: News Article

Product Description

Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30862055/).

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Chile | Colombia | Dominican Republic | European Medicines Agency | Germany | Hungary | India | Ireland | Italy | Lithuania | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | Spain | Sweden | Taiwan | United Kingdom | Venezuela

Approved Indications: Multiple Sclerosis

Known Adverse Events: Depressive Disorder | Pain Unspecified | Dermatitis | Nasopharyngitis | Pharyngitis | Lymphadenopathy | Dermatitis, Atopic | Respiratory Tract Infections | Bronchitis | Influenza, Human

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Daclizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

03/07/2024

News Article

 Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer

03/29/2022

News Article

 Organ Care Products Market Size Worth $272.16 Mn, Globally, by 2028 at 15.6% CAGR - Exclusive Report by The Insight Partners

12/15/2021

News Article

 North American MS Drugs Market, Forecast to 2027 by Drug Type, Class & Category; RoA; MS Type; Distribution Channel; and Country

12/15/2021

News Article

 Multiple Sclerosis (MS) Drugs Market in North America to Cross $15.65 Billion by 2027 - Annual Revenue Insights (2017-2027) for Both Immunomodulators and Immunosuppressants

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions